# ATOPIC DERMATITIS RESEARCH NETWORK LEADERSHIP CENTER

> **NIH NIH UM1** · NATIONAL JEWISH HEALTH · 2022 · $3,724,397

## Abstract

PROJECT SUMMARY/ABSTRACT
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in the general population. AD is
associated with defective skin barrier function, microbial dysbiosis, as well as various cutaneous immune
abnormalities including type 2 inflammation and decreased cutaneous host defense. These abnormalities
translate into multiple phenotypes and endotypes that are not fully defined and therefore, effective targeted
therapies, beyond type 2 immune blockade, to reverse these various subsets of AD are lacking. Beyond its
effects on cutaneous defense, AD is associated with systemic inflammation and appears to be the first step in
the development of other atopic conditions including food allergy and asthma.
This grant application is being submitted in response to RFA-AI-19-014, Atopic Dermatitis Research
Network-Leadership Center (ADRN-LC). The goal of this proposal is to create an ADRN-LC which will
provide the overall scientific strategy and organizational structure to the ADRN and will interact closely with
the ADRN Clinical Research Centers (ADRN-CRCs), to support the conduct of multi-site clinical studies and
trials that will elucidate mechanisms of skin barrier dysfunction and cutaneous immune responses in
atopic dermatitis (AD).
The central hypothesis in this application is that different phenotypes and endotypes of AD are
associated with distinct defects in their skin barrier, microbiome, and skin immune responses which can
be characterized by novel approaches to skin sampling and open up avenues for paradigm shifting
therapeutic interventions to benefit patients with severe persistent AD. We will achieve our objectives
with the following Aims:
· Specific Aim 1: To establish an Administrative and Clinical Research Operations Leadership
 Center that will be responsible for implementation, coordination, and funding of clinical trials and
 studies for the ADRN-LC in research areas evaluating mechanism and treatment of AD.
· Specific Aim 2: To develop a Network-wide multi-center ADRN clinical trial to evaluate the long-
 term effects of targeted microbiome transplantation on clinical outcomes in AD as well as epithelial
barrier function, microbial dysbiosis, and cutaneous immunity.
· Specific Aim 3: To design a Network-wide ADRN one-year observational study to assess the
 stability of AD phenotypes/endotypes using a Network correlation analysis of transcriptomics
 (conventional and single cell RNA sequencing), skin tape proteomics, lipidomics, and microbiome
 over time in subjects with persistent mild vs. persistent severe AD and assessment of therapeutic
responses to topical corticosteroids and Dupilumab.
· Specific Aim 4: To carry out a Network-wide multi-center ADRN clinical trial to examine the effects
 of targeted IL-1 blockade on the clinical outcome, skin microbiome, epithelial skin barrier, and
cutaneous immune response in AD patients who have an inadequate response to IL-4/IL-13 blockade
using Dupilumab th...

## Key facts

- **NIH application ID:** 10382408
- **Project number:** 5UM1AI151958-03
- **Recipient organization:** NATIONAL JEWISH HEALTH
- **Principal Investigator:** Donald YM Leung
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $3,724,397
- **Award type:** 5
- **Project period:** 2020-04-09 → 2027-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10382408

## Citation

> US National Institutes of Health, RePORTER application 10382408, ATOPIC DERMATITIS RESEARCH NETWORK LEADERSHIP CENTER (5UM1AI151958-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10382408. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*